Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Sickle Cell Disease Competitive Landscape Report 2026: Comprehensive Analysis of Over 40 Companies and More Than 50 Drugs

globenewswire.com
NVS Novartis is mentioned for its work on ADAKVEO and Canakinumab for sickle cell disease, indicating ongoing development and product focus in this area. PFE Pfizer is highlighted for developing Inclacumab to reduce vaso-occlusive crises in sickle cell disease patients, showing active engagement in the therapeutic landscape. AGIO Agios Pharmaceuticals is developing Mitapivat, a drug targeting red blood cell deformation in sickle cell disease, indicating a focus on innovative treatments. CRSP CRISPR Therapeutics is identified as a key player in developing transformative therapies for sickle cell disease, suggesting a strong position in gene editing for this condition. TAK Takeda is mentioned for its early-stage product TAK-755 in sickle cell disease research, indicating a minor but present involvement in the field.

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Sickle Cell Disease - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering.

The report offers a comprehensive analysis of over 40 companies and more than 50 drugs within the competitive landscape for sickle cell disease (SCD). This report evaluates therapeutics based on product type, stage of development, route of administration, and molecule type, while also shedding light on inactive pipeline products.

Geographical Coverage: Global

Sickle cell disease is a severe hereditary condition affecting hemoglobin in red blood cells. People with SCD inherit a gene defect from each parent, leading to the presence of atypical hemoglobin molecules, which in turn cause red blood cells to adopt a sickle shape. This distortion leads to several complications, including anemia due to the rapid destruction of red blood cells.

Testing for SCD can occur pre-birth or at any age, with varying methods depending on patient age. Available treatments aim to prevent crises, alleviate symptoms, and forestall complications, utilizing pain management medications, blood transfusions, and possibly bone marrow transplants. Researchers are pursuing groundbreaking gene therapies to amend the genetic defect or promote the production of fetal hemoglobin.

Report Highlights

Company and Product Profiles

Novartis: Known for using innovative technologies, Novartis is committed to groundbreaking treatments like ADAKVEO, which minimizes pain crises in SCD patients by targeting the P-selectin protein.

Pfizer: Focuses on the development of innovative therapies like Inclacumab, an antibody aiming to reduce vaso-occlusive crises in SCD patients.

Agios Pharmaceuticals: Developing Mitapivat, a drug targeting the biochemical pathways causing red blood cell deformation in SCD.

Novartis: Also, developing Canakinumab, an anti-inflammatory monoclonal antibody for cardiovascular and SCD-related treatments.

Analytical Perspective

The report provides an in-depth commercial assessment of drugs, including collaboration, agreements, licensing, and acquisitions. It offers comparative evaluations of companies based on therapy type, development stage, and technology.

Key Questions Addressed

Key Players: CRISPR therapeutics, Bluebird Bio, Pfizer, Novo Nordisk, Agios Pharmaceuticals, among others, are at the forefront of developing transformative therapies in the SCD treatment landscape.

Key Products: Include CTX001, LentiGlobin BB305, Inclacumab, Etavopivat, Mitapivat, among several other promising therapeutic candidates.

Companies Featured

Key Topics Covered:

Introduction

Executive Summary

Sickle Cell Disease: Overview

Sickle Cell Disease - Analytical Perspective: In-depth Commercial Assessment

Competitive Landscape

Therapeutic Assessment

Sickle Cell Disease: Company and Product Profiles (Marketed Therapies)

Novartis

ADAKVEO

Sickle Cell Disease: Company and Product Profiles (Pipeline Therapies)

Late Stage Products (Phase III)

Pfizer

Inclacumab

Mid Stage Products (Phase II)

Novartis

Canakinumab

Early Stage Products (Phase I)

Takeda

TAK-755

Preclinical and Discovery Stage Products

Company Name

Product Name

Inactive Products

Sickle Cell Disease- Unmet needs

Sickle Cell Disease - Market drivers and barriers

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/knw8i9

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.